BLACKSMITH MEDICINES ANNOUNCES ONCOLOGY SCIENTIFIC ADVISORS
SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced additions to its science advisory team to help advance its emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.
- SAN DIEGO, Jan. 5, 2023 /PRNewswire/ -- Blacksmith Medicines, Inc. (Blacksmith), a leading biopharma dedicated to discovering and developing medicines targeting metalloenzymes, today announced additions to its science advisory team to help advance its emerging precision oncology programs focused on novel synthetic lethality targets involved in the DNA Damage Response.
- Additions to Blacksmith's oncology scientific advisors include:
Jeff Hager, Ph.D. - Former Evotec Head of Oncology and Director of Chemistry at British Biotech
"We are honored to work with such an outstanding group of biotechnology leaders on our oncology scientific advisors board, who share our passion to develop novel medicines against undrugged metalloenzyme targets with next-generation chemistries," said Zachary Zimmerman, Ph.D., CEO and co-founder of Blacksmith. - We look forward to their contributions as we grow Blacksmith and expand on our capabilities in precision oncology."